Additional tumors found with blue light
A secondary outcome analysis of the OR data showed blue light rigid cystoscopy with HAL detected additional tumors compared with white light cystoscopy in 30 patients (46.2%). Of the 26 patients with confirmed CIS, nine (34.6%) had their lesion detected only with blue light cystoscopy (p<.0001).
The incidence of adverse events considered causally related to blue light and/or HAL was low both in the surveillance examination (2.0%) and in the OR examination (2.9%).
“There were no indications of increased adverse events with repeated blue light cystoscopy,” Dr. Daneshmand said.
Surgeons were also asked how findings of the surveillance cystoscopy under blue light might have influenced their management of a patient in clinical practice. They were given four response options, and the results showed that one-third of the time, the findings would have caused surgeons to change their management.
Patient-reported outcome data were collected as well. For both the blue light surveillance exam and OR exam, about 90% of patients felt the procedure was worthwhile, said they would undergo it again, and would recommend it to others.
Dr. Daneshmand is a paid consultant to Photocure. Several of his co-authors are scientific study/trial participants for Photocure and/or have a financial or other relationship with several pharmaceutical companies.
More from Urology Times:
Subscribe to Urology Times to get monthly news from the leading news source for urologists.